Is Nureca a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Nureca Ltd is a average quality company .

Is Nureca undervalued or overvalued?

The key valuation ratios of Nureca Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone .

What is Nureca share price return in the past 10 years?

Data is not available for this company

Is Nureca a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Nureca Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

Nureca Ltd - Stock Valuation and Financial Performance

Name: Nureca
Brand: Nureca

BSE: 543264 | NSE: NURECA | Medical Equipment/Supplies/Accessories | Small Cap

Place order

Nureca Ltd. Share Price

₹277 -2.10 -0.75%
as on 26-Dec'24 16:59

10 Year X-Ray of Nureca Ltd.:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	103.9%	92.4%	76%	67.7%	33.6%	-5.3%	-1.5%	-
Value Creation Index ⓘ	6.4	5.6	4.4	3.8	1.4	-1.4	-1.1	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	0.6	0.7	99.4	213	256	112	94.5	98
Sales YoY Gr.	-	23.7%	13,520.6%	114.6%	19.8%	-56.2%	-15.5%	-
Adj EPS ⓘ	2.2	2.8	911.6	46.6	44.7	-10.1	-6.6	-3.8
YoY Gr.	-	26.5%	32226.6%	-94.9%	-4.1%	-122.5%	NA	-
BVPS (₹) ⓘ	3.3	6.4	1,995.7	163.3	203.7	195.3	192.9	193.4
Adj Net Profit ⓘ	0	0	6.4	46.6	44.7	-10.1	-6.6	-4
Cash Flow from Ops. ⓘ	0	0.1	-7.9	35.1	1.8	12.1	-3	-
Debt/CF from Ops. ⓘ	0	0	-1.2	0	0.6	0	-0.1	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	NA	164.5%	-23.8%	-15.5%
Adj EPS ⓘ	NA	-218.4%	-152%	NA
BVPSⓘ	NA	97.7%	5.7%	-1.2%
Share Price	-	-	-41.6%	-37.2%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	60.4	54.4	85	52.3	24.4	-5.1	-3.4	-2
Op. Profit Mgn % ⓘ	4	4.2	9.8	29.4	22.1	-13.5	-11.3	-15.1
Net Profit Mgn % ⓘ	2.7	2.7	6.4	21.9	17.5	-9	-6.9	-3.9
Debt to Equity ⓘ	0	0	0.7	0	0	0	0	0
Working Cap Days ⓘ	0	360	60	83	130	291	203	348
Cash Conv. Cycle ⓘ	0	104	39	38	58	141	102	328

Recent Performance Summary

No data to display

Return on Equity is Poor

Sales growth has been subdued in last 3 years -23.76%

Sales growth is not so good in last 4 quarters at -3.61%

Latest Financials - Nureca Ltd.

	Standalone	Consolidated
TTM EPS (₹)	-3.8	-2.8
TTM Sales (₹ Cr.)	97.6	90.8
BVPS (₹.) ⓘ	193.4	194.3
Reserves (₹ Cr.) ⓘ	183	184
P/BV ⓘ	1.43	1.43
PE ⓘ	0.00	0.00

From the Market
52 Week Low / High (₹)	240.90 / 468.25
All Time Low / High (₹)	240.90 / 2316.60
Market Cap (₹ Cr.)	277
Equity (₹ Cr.)	10
Face Value (₹)	10
Industry PE ⓘ	76.5

Management X-Ray of Nureca Ltd.:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Nureca Ltd.

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Nureca Ltd.

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	1	1	99	213	256	112	95
Operating Expenses ⓘ	1	1	90	152	200	127	106
Manufacturing Costs	0	0	0	14	2	1	1
Material Costs	0	1	65	99	133	78	67
Employee Cost	0	0	3	5	10	16	12
Other Costs ⓘ	0	0	22	34	56	33	26
Operating Profit ⓘ	0	0	10	62	56	-15	-11
Operating Profit Margin (%)	4.0%	4.2%	9.8%	28.9%	21.8%	-13.8%	-11.8%
Other Income ⓘ	0	0	0	3	8	7	11
Interest ⓘ	0	0	1	2	1	0	0
Depreciation ⓘ	0	0	0	0	1	2	2
Exceptional Items ⓘ	0	0	0	0	0	0	0
Profit Before Tax ⓘ	0	0	9	62	61	-11	-3
Tax ⓘ	0	0	2	16	16	-3	-1
Profit After Tax	0	0	6	47	45	-8	-2
PAT Margin (%)	2.7%	2.8%	6.4%	21.8%	17.7%	-7.5%	-2.6%
Adjusted EPS (₹)	2.2	3.0	915.7	46.5	45.3	-8.4	-2.4
Dividend Payout Ratio (%)	0%	0%	0%	4%	7%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	0	0	14	163	204	195	193
Share Capital ⓘ	0	0	0	10	10	10	10
Reserves ⓘ	0	0	14	153	194	185	183
Minority Interest	0	0	0	0	0	0	0
Debt	0	0	9	1	0	0	0
Long Term Debt	0	0	9	1	0	0	0
Short Term Debt	0	0	0	0	0	0	0
Trade Payables	0	1	6	9	5	5	5
Others Liabilities ⓘ	0	0	5	27	44	4	1
Total Liabilities ⓘ	0	1	34	200	252	204	199
Fixed Assets
Gross Block	0	0	1	4	11	10	10
Accumulated Depreciation	0	0	0	0	2	2	4
Net Fixed Assetsⓘ	0	0	1	3	10	8	6
CWIP ⓘ	0	0	0	0	0	0	0
Investmentsⓘ	0	0	0	1	34	62	97
Inventories	0	1	16	37	63	33	29
Trade Receivables	0	0	13	0	3	4	2
Cash Equivalents ⓘ	0	0	0	126	84	71	45
Others Assetsⓘ	0	0	3	32	58	26	21
Total Assets ⓘ	0	1	34	200	252	204	199

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	-8	35	2	12	-3
PBT ⓘ	9	62	61	-11	-3
Adjustment ⓘ	1	0	-4	-4	-7
Changes in Working Capital ⓘ	-18	-12	-38	31	6
Tax Paid ⓘ	0	-15	-18	-4	1
Cash Flow From Investing Activity ⓘ	0	-110	-3	-18	18
Capex	0	0	-6	0	0
Net Investments	0	-109	-1	-17	9
Others ⓘ	0	-1	4	-1	9
Cash Flow From Financing Activityⓘ	8	92	-7	-2	-1
Net Proceeds from Shares ⓘ	0	105	0	0	0
Net Proceeds from Borrowing ⓘ	-1	-13	-1	0	0
Interest Paid ⓘ	-1	-1	0	0	0
Dividend Paid ⓘ	0	0	-5	0	0
Others ⓘ	9	1	-1	-1	-1
Net Cash Flow ⓘ	0	17	-9	-8	14

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	N/A	N/A	91.48	52.5	24.69	-4.22	-1.26
ROCE (%)	N/A	N/A	76	67.74	33.61	-5.26	-1.45
Asset Turnover Ratio	1.75	0.9	5.89	1.92	1.19	0.51	0.51
PAT to CFO Conversion(x)	N/A	N/A	-1.33	0.74	0.04	N/A	N/A
Working Capital Days
Receivable Days	87	68	23	11	2	11	11
Inventory Days	80	241	30	43	68	150	110
Payable Days	231	529	20	27	19	23	27

Nureca Ltd Stock News

Nureca Ltd FAQs

What is the share price of Nureca Ltd.?

Company share prices are keep on changing according to the market conditions. The closing price of Nureca Ltd. on 26-Dec-2024 16:59 is ₹277.0.

What is the market cap of Nureca Ltd.?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 26-Dec-2024 16:59 the market cap of Nureca Ltd. stood at ₹277.0.

What is the P/E ratio of Nureca Ltd.?

The latest P/E ratio of Nureca Ltd. as of 26-Dec-2024 16:59 is 0.00.

What is the P/B ratio of Nureca Ltd.?

The latest P/B ratio of Nureca Ltd. as of 26-Dec-2024 16:59 is 1.43.

What is the 52-week high and low of Nureca Ltd.?

The 52-week high of Nureca Ltd. is ₹468.2 and the 52-week low is ₹240.9.

What is the TTM revenue of Nureca Ltd.?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Nureca Ltd. is ₹97.62 ( Cr.) .

About Nureca Ltd

Nureca is a B2C company engaged in the business of home healthcare and wellness products, which offers quality, durability, functionality, usability and innovative designs. It enables its customers with tools to help them monitor chronic ailments and other diseases, to improve their lifestyle. It is a digital first company wherein it sells its products through online channel partners such as e-commerce players, distributors and retailer. Further, it also sells its products through its own website drtrust.in.

The company has most of the product lines supporting home health market in India, making it a one-stop solution provider. Dr Trust is a known for its innovative products in the market, and, with the segment showing significant potential for growth, the company is positioned to show significant growth.

The company has a diversified product portfolio, which primarily caters to home healthcare sector. It provides an improved product mix to its customers and their preferences thereby targeting a wider customer base. Its growth is further driven by its ability to make available an assortment of quality products under trusted brands built by the company.

Products:

Currently, the company classify its products portfolio under the following five categories such as:

Chronic Device Products - which includes products such as blood pressure monitors, pulse oximeters, thermometers, nebulizers, self monitoring glucose devices, humidifier and steamers.
Orthopedic Products - which includes rehabilitation products such as wheelchairs, walkers, lumbar and tailbone supports and physiotherapy electric massagers.
Mother and Child Products - which includes products such as breast pumps, bottle sterilizers, bottle warmers, car seats and baby carry cots.
Nutrition Supplements - which includes products such as fish oil, multivitamins, probiotics, botin, apple cider and vinegar.
Lifestyle Products - which includes products such as smart scales, aroma diffusers and fitness tracker.

Key awards, recognitions and accreditations

2020: The company received ISO 9001:2015 Certificate of Registration from Intertek Certification Limited for Management System, which is applicable to sales, services and warehousing of medical devices, consumer electronics, pharmaceutical and personal care products.
2020: Appreciation Letter from Pharmaceuticals Export Promoter Council of India stating the company as a very dynamic and evolving medical devices company and has created a credible and leading brand ‘Dr. Trust’ which is now a household name in India.

Major events and milestones:

2016: Online launch of Dr. Trust Brand.
2017: Launched Dr. Physio brand in electric massager categories and Trumom brand in mother and child care categories.
2017: Started three flex centres in Punjab, Karnataka and Uttar Pradesh.
2018: The company became the wholly owned subsidiary of Nectar Biopharma Private Limited.
2018: Added three flex centres in Chandigarh, Telangana and Maharashtra.
2018: Secured warehouse drug license.
2020 Transfer and vesting of Specified Undertaking (as defined under the Scheme) from Nectar Biopharma Private Limited to the company pursuant to the Scheme of Arrangement.